オプションチェーンは、bluebird bioの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、bluebird bioの市場センチメントを評価します。.

bluebird bio (NASDAQ:BLUE) 株価情報, オプションチェーン

bluebird bio

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

bluebird bio Inc

BLUE HOLDINGS INC by Blue Holdings, Inc.

BLUE WORLD ACQUISITION CORP USD RTS

BLUERIVER ACQUISITION CORP CL A ORD SHS

BLUESCAPE OPPORTUNITIES ACQUISITION CORP CL A

Blue Apron Holdings Inc COM PAR $

Blue Biofuels Inc

Blue Bird Corp

Blue Capital Reinsurance Holdings Ltd

BLUE DIAMOND VENTURES INC by Blue Diamond Ventures, Inc.

Blue Diamond Ventures Inc

BLUE DOLPHIN ENERGY CO by Blue Dolphin Energy Co.

Blue Dolphin Energy Co

BLUE EARTH RES INC by Blue Earth Resources, Inc.

Blue Earth Resources Inc

Blue Energy Ltd

Blue Foundry Bancorp

BLUE GEM ENTERPRISE by Blue Gem Enterprise

Blue Gem Enterprise

Blue Hat Interactive Entertainment Technology - Ordinary Shares

Blue Hat Interactive Entertainment Technology

CANOPUS BIOPHARMA INC by Canopus Biopharma, Inc.

Blue Heaven Coffee Inc

BLUE HORIZON GLOBAL CAP by BLUE HORIZON GLOBAL CAP CORP.

Blue Horizon Global Capital Corp

BLUE LAGOON RESOURCES INC by Blue Lagoon Resources Inc.

Blue Lagoon Resources Inc

BLUE LINE PROTECTION GRP by Blue Line Protection Group, Inc.

Blue Line Protection Group Inc

BLUE MOON GRP UNSP/ADR by Blue Moon Group Holdings Limited

Blue Moon Group Holdings Ltd

Blue Moon Metals Inc

BLUE MOON METALS INC by BLUE MOON METALS INC.

BLUE NOTE MINING INC NEW by Blue Note Mining Inc.

Blue Note Mining Inc

Blue Ocean Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Blue Ocean Acquisition Corp

Blue Ocean Acquisition Corp Warrants (02/12/2026)

Blue Ocean Acquisition Corp Ordinary Shares - Class A

Blue Owl Capital Corporation Common Stock

Blue Owl Capital Corp

Blue Owl Capital Inc. Class A Common Stock

Blue Owl Capital Inc

Blue Ribbon Income Fund

Blue Ridge Bankshares Inc

BLUE RIDGE REAL ESTATE CO by Blue Ridge Real Estate Co.

Blue Ridge Real Estate Co

BLUE RIVER RES LTD ORD by Blue River Resources, Ltd.

Blue River Resources Ltd

BLUE SKY URANIUM CORP by Blue Sky Uranium Corp.

Blue Sky Uranium Corp

Blue Sphere Corp

BLUE STAR FOODS CORP by BLUE STAR FOODS CORP.

Blue Star Foods Corp

BLUE STAR GLOBAL INC by Blue Star Global, Inc.

Blue Star Global Inc

BLUE STAR GOLD CORP by Blue Star Gold Corp.

Blue Star Gold Corp

BLUE STAR HELIUM LTD by Blue Star Helium Ltd.

Blue Star Helium Ltd

BLUE STAR OPPTYS CORP by Blue Star Opportunities Corp.

Blue Star Opportunities Corp

BLUE WATER GLOBAL GRP INC by Blue Water Global Group, Inc.

Blue Water Global Group Inc

BLUE WATER PETROLEUM CP by Blue Water Petroleum Corp.

Blue Water Petroleum Corp

BLUE WATER VENTURES INC by Blue Water Ventures International, Inc.

Blue Water Ventures International Inc

Blue World Acquisition Corp Warrants (10/01/2029)

Blue World Acquisition Corp

Blue World Acquisition Corp Units (1 Ord Class A & 1/2 War & 1 Right)

BLUEFIRE EQUIPMENT CORP by BlueFire Equipment Corp.

BlueFire Equipment Corp

BLUEHARBOR BANK (NC) by BlueHarbor Bank (Mooresville NC)

BlueHarbor Bank

BlueLinx Holdings Inc

BLUERIVER ACQ CORP A by BlueRiver Acquisition Corp.

BlueRiver Acquisition Corp

BlueRiver Acquisition Corp Warrants (04/01/2026)

BlueRiver Acquisition Corp Units (1 Ord Share Class A & 1/3 War)

BlueRush Inc

BLUESCOPE STEEL LTD by Bluescope Steel, Ltd.

BlueScope Steel Ltd

BLUESCOPE STL UNS/ADR NEW by Bluescope Steel, Ltd.

BLUEBERRIES MEDICAL CO by Blueberries Medical Co.

Blueberries Medical Corp

Bluegreen Vacations Holding Corp Class B

Bluegreen Vacations Holdings Corp Com Cl A

Bluejay Diagnostics Inc

Blueone Card Inc

Blueprint Chesapeake Multi-Asset Trend ETF

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

BLUEPRINT TECHS INC by Blueprint Technologies, Inc.

Blueprint Technologies Inc

Bluerock Homes Trust, Inc. Class A Common Stock

Bluerock Homes Trust Inc

BLUESKY DIGITAL ASSET CRP by Bluesky Digital Assets Corp.

Bluesky Digital Assets Corp

BLUESTEM GROUP INC by Bluestem Group Inc.

Bluestem Group Inc

Bluestone Resources Inc

BLUE

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<ul>
<li>Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially transformative and durable clinical impact</li>
<li>Results from first and only focused analysis of patients with sickle cell disease with a history of overt or silent stroke (n=27) show no stroke recurrence through 9 years of follow-up (n=2)</li>
</ul>

News

Reported Sunday, bluebird bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024

bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO&#x2122;) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
Treatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have &gt;5 years of follow-up

bluebird bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or Near-Normal Adult Hb Levels At ASH Meeting

<h3>Gainers</h3>
<ul>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock rose 168.9% to $9.52 during Thursday's pre-market session. The company's market cap stands at $196.3 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock moved upwards by 67.86% to $6.53. The market value of their outstanding shares is at $3.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 30.95% to $3.3. The market value of their outstanding shares is at $2.7 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock increased by 16.43% to $14.81. The company's market cap stands at $673.4 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock increased by 15.0% to $6.9. The company's market cap stands at $143.5 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock increased by 13.38% to $11.0. The market value of their outstanding shares is at $90.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock fell 32.4% to $0.5 during Thursday's pre-market session. The company's market cap stands at $96.8 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock declined by 24.26% to $4.81. The company's market cap stands at $13.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock declined by 12.0% to $1.32. The company's market cap stands at $9.1 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock decreased by 11.91% to $1.85. The market value of their outstanding shares is at $37.4 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) shares decreased by 11.08% to $3.13. The market value of their outstanding shares is at $27.9 million. </li>
<li>Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) stock decreased by 10.5% to $18.0. The company's market cap stands at $4.9 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADVM

BJDX

BRTX

CAPR

Envoy Medical, Inc. - Class A Common Stock

COCH

CRVO

CYCN

MRKR

STVN

TARA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of Verint Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) rose sharply in today's pre-market trading after the company reported a year-over-year increase in third-<a href="https://www.benzinga.com/insights/earnings/24/12/42326587/verint-systems-earnings-analysis-q3-recap">quarter financial results</a>.
Verint Systems posted adjusted earnings of 39 cents per share, up from year-ago earnings of 12 cents per share. The company's sales rose to $224.193 million from $218.547 million.
Verint Systems shares jumped 23.2% to $32.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) gained 161.5% to $7.01 in pre-market trading after the company announced changes in management including new CFO and CEO appointees.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) rose 72.4% to $4.43 in pre-market trading after dipping more than 10% on Wednesday.</li>
<li>Mawson Infrastructure Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) gained 47.1% to $1.00 in pre-market trading. Mawson Infrastructure Disclosed Australian creditors filed involuntary Chapter 11 petition against the company.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) gained 21.3% to $15.43 in pre-market trading after dipping 23% on Wednesday.</li>
<li>Alset Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) gained 17.5% to $1.41 in pre-market trading.</li>
<li>BTC Digital Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) rose 13.9% to $18.24 in pre-market trading after gaining 9% on Wednesday.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) gained 13.8% to $119.48 in pre-market trading as the company reported better-than-expected results for its third quarter and issued strong guidance for fiscal 2024. The company also announced the appointment of Winnie Park as CEO and a member of its board of directors, effective Dec. 16, 2024.</li>
<li>ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) climbed 10.6% to $1.35 in pre-market trading after the company reported better-than-expected third-quarter sales results.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 10.4% to $1.89 in pre-market trading. BranchOut Food signed a LOI and received $250,000 PO from a leading ingredient distributor.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares tumbled 38.2% to $0.4550 in pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) declined 26.9% to $0.2924 in pre-market trading after jumping 105% on Wednesday.</li>
<li>Cyclerion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares fell 23.2% to $4.88 in pre-market trading after jumping 294% on Wednesday.</li>
<li>Phoenix Motor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares fell 21.4% to $0.2890 in pre-market trading after gaining 13% on Wednesday.</li>
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) fell 21.4% to $0.4089 in pre-market trading after gaining over 63% on Wednesday.</li>
<li>SRM Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) fell 20.7% to $0.92 in pre-market trading after climbing 84% on Wednesday.</li>
<li>nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) fell 18.7% to $34.50 in pre-market trading after the company reported third-quarter financial results and issued fourth-quarter revenue guidance below estimates.</li>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) dipped 16.3% to $0.4273 in pre-market trading after jumping 62% on Wednesday.</li>
<li>SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) shares dipped 14.7% to $24.45 in pre-market trading following third-quarter results.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) fell 14.4% to $17.59 in today's pre-market trading after the company reported a year-over-year decrease in third-quarter sales results. Also, the company said it expects a 4% decrease in fourth-quarter total revenue.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42332881/dow-settles-above-45000-for-first-time-investor-sentiment-improves-fear-greed-index-in-greed-zone">Dow Settles Above 45,000 For First Time As Salesforce, Marvell Surge: Investor Sentiment Improves, Fear Index In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

BTCT

CHPT

CNEY

FIVE

HTOO

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

NCNO

PRFX

VRNT

Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

Stock Split

bluebird bio Announces 1-for-20 Reverse Stock Split To Become Effective 5 p.m. ET On Dec. 12

The Biden-Harris administration has announced an initiative to improve access to gene therapies for <a href="https://www.benzinga.com/topic/sickle-cell-disease">sickle cell disease</a> under the Cell and Gene Therapy Access Model.
This voluntary model, developed by the Center for Medicare and Medicaid Innovation, seeks to enhance access to these therapies, improve patient outcomes, and reduce healthcare costs by tying payments to treatment efficacy for Medicaid recipients.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42243241/fda-probes-potential-life-threatening-blood-cancer-risks-linked-to-bluebird-bios-skysona-gene-therapy" rel="noreferrer noopener">FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio&#8217;s Skysona Gene Therapy</a>
Two drug manufacturers, Bluebird Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), have agreed to participate in the model with their FDA-approved therapies, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016766/jp-morgan-downgrades-gene-therapy-focused-bluebird-bio-cites-limited-funding-options" rel="noreferrer noopener">Lyfgenia</a> and <a target="_blank" href="https://www.benzinga.com/news/24/01/36657324/gene-therapy-for-beta-thalassemia-crispr-therapeuticsvertexs-casgevy-secures-fda-nod-ahead-of-schedu" rel="noreferrer noopener">Casgevy</a>.
CMS is working to <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-steps-increase-access-sickle-cell-disease-treatments" rel="noreferrer noopener">engage</a> states and U.S. territories enrolled in the Medicaid Drug Rebate Program, providing technical support and data infrastructure for implementation.
States may apply to participate starting this month, with applications accepted until Feb. 28, 2025.
Over 100,000 individuals in the U.S. live with sickle cell disease, more than half of whom rely on Medicaid. The disease significantly reduces life expectancy and imposes an annual economic burden of nearly $3 billion in healthcare costs.
The Food and Drug Administration (FDA) approved Lyfgenia and Casgevy in December 2023 as gene therapies targeting <a href="https://www.benzinga.com/general/biotech/23/12/36156713/fda-approves-first-gene-editing-cell-therapy-for-sickle-cell-disease-an-inherited-blood-disorder" target="_blank" rel="noreferrer noopener">sickle cell disease</a>.
Launching in January 2025, the model allows states to join until January 2026. States can also apply for optional funding to support implementation.
This initiative aligns with President Biden's 2022 Executive Order to expand access to novel therapies and reduce prescription drug costs. Future expansions of the model may include other cell and gene therapies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42321484/fords-mustang-mach-e-sales-skyrocket-383-in-november-amid-growing-ev-momentum" target="_blank" rel="noreferrer noopener">Ford&#8217;s Mustang Mach-E Sales Skyrocket 38.3% In November Amid Growing EV Momentum</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

VRTX

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program

WIIM

Bluebird Bio shares are trading higher after the company announced it joined the CMMI cell and gene therapy access model and will offer outcomes-based agreements to expand Medicaid access to LYFGENIA gene therapy for sickle cell disease.

bluebird bio Joins CMMI Cell And Gene Therapy Access Model, Offering Outcomes-Based Agreements To Expand Medicaid Access To LYFGENIA Gene Therapy For Sickle Cell Disease, With States Able To Opt In Until February 2025

On Wednesday, the FDA raised concerns about life-threatening hematologic malignancies in patients treated with Bluebird Bio Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) Skysona (elivaldogene autotemcel), a gene therapy for early, active cerebral adrenoleukodystrophy (CALD).
In September 2022, the FDA approved Bluebird Bio&#8217;s&nbsp;Skysona, aka eli-cel, to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/22/09/28905729/fda-just-okayed-bluebird-bios-3m-gene-therapy-for-rare-neurological-disorder-in-boys-what-investo?_gl=1&#x2A;f5q6x4&#x2A;_gcl_au&#x2A;MzM1NjU4Njk2LjE3MjExMjI2MjY.&#x2A;_ga&#x2A;MTA5NjUzODQ1My4xNzIxMTIyNjI2&#x2A;_ga_V7ZK73W7N0&#x2A;MTcyODYzNTY2NS40MDcuMS4xNzI4NjM2NTAyLjAuMC4w" rel="noreferrer noopener">cerebral adrenoleukodystrophy (CALD</a>).
The agency has received reports of myelodysplastic syndrome and acute myeloid leukemia linked to Skysona, with cases emerging 14 to 92 months post-treatment during clinical trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016766/jp-morgan-downgrades-gene-therapy-focused-bluebird-bio-cites-limited-funding-options" rel="noreferrer noopener">JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options</a>
As per new data released in October, seven out of 67 children treated with&nbsp;Bluebird Bio&#8217;s gene therapy for a severe neurological disorder in clinical trials <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41290857/worries-mount-over-cancer-risks-in-bluebird-bios-gene-therapy" rel="noreferrer noopener">developed blood cancers</a>.
The FDA is investigating these risks, which include hospitalization, the need for allogeneic hematopoietic stem cell transplantation, and fatal outcomes. Healthcare providers are urged to consider alternative therapies, such as allogeneic stem cell transplants, for patients with suitable, matched donors before opting for Skysona treatment.
Skysona&#8217;s U.S. prescribing information <a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-hematologic-malignancy-following-skysona-elivaldogene-autotemcel" rel="noreferrer noopener">features</a> a Boxed Warning about the serious risk of hematologic malignancies and additional warnings under the Clinical Trials Experience section.
Patients and clinical trial participants treated with Skysona are advised to undergo lifelong monitoring for malignancies.
To detect potential malignancies early, the FDA recommends regular complete blood counts every three months and assessments for clonal expansion twice within the first year post-treatment.
Annual follow-ups and bone marrow evaluations are also advised as clinically necessary.
In September, Bluebird bio announced it is implementing a restructuring to optimize its cost structure and enable quarterly cash flow break-even in the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40998565/bluebird-bio-initiates-restructuring-intended-to-optimize-cost-structure-and-enable-quarterly-cash" rel="noreferrer noopener">second half of 2025</a>.
The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in the third quarter of 2025, compared to the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41008825/gene-therapy-focused-bluebird-bio-restructures-cuts-is-workforce-by-25-seeks-to-breakeven-next-ye" rel="noreferrer noopener">prior reporting period</a>.
Price Action: BLUE stock is up 1.64% at $0.3840 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42241802/geopark-seals-530-million-colombian-oil-gas-asset-acquisition-from-repsol" target="_blank" rel="noreferrer noopener">GeoPark Seals $530 Million Colombian Oil &amp; Gas Asset Acquisition Deal With Repsol</a></li>
</ul>
Image via Unsplash

Equities

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy

bluebird bio shares are trading lower after the FDA announced an investigation into a serious risk of hematologic malignancy following Skysona.

<a href="https://www.fda.gov/media/161640/download">https://www.fda.gov/media/161640/download</a>
&nbsp;
WARNING: HEMATOLOGIC MALIGNANCY Hematologic malignancy, including life-threatening cases of myelodysplastic syndrome, has occurred in patients treated with SKYSONA. Patients have been diagnosed between 14 months and 7.5 years after SKYSONA administration, and the cancers appear to be the result of the SKYSONA lentiviral vector, Lenti-D, integration in proto-oncogenes. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through assessments for evidence for clonal expansion or predominance at least twice in the first year and annually thereafter; consider bone marrow evaluations as clinically indicated [see Warnings and Precautions (5.1)].

FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)

On Thursday, Bluebird Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41967541/bluebird-bio-reports-third-quarter-2024-results-and-highlights-operational-progress-and-2024-guida" rel="noreferrer noopener">consensus loss of 36 cents</a>.
The gene therapy company reported sales of $10.6 million, down from $12.39 million, missing the consensus of $18.1 million.
The company&#8217;s cash, cash equivalents, and restricted cash balance were approximately&nbsp;$118.7 million, which is expected to provide a cash runway into the first quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41290857/worries-mount-over-cancer-risks-in-bluebird-bios-gene-therapy" rel="noreferrer noopener">Worries Mount Over Cancer Risks in Bluebird Bio&#8217;s Gene Therapy</a>
The company anticipates quarterly cash flow break-even in the second half of 2025, assuming it scales to approximately 40 drug product deliveries per quarter and obtains additional cash resources to extend its runway.
JP Morgan downgraded Bluebird after the third-quarter results. The analyst notes a reduced cash runway to &#8220;into 1Q25&#8221; from &#8220;into 2Q25.&#8221;
JP Morgan highlights that Bluebird did achieve the milestone of its first Lyfgenia infusion during the quarter (and revenue recognition) and continues to increase the pace of patient starts (cell collections) across its portfolio but is doing so against a backdrop of continued negative gross margins.
<ul>
<li>57 patient starts completed to date in 2024 (35 Zynteglo, 17 Lyfgenia, 5 Skysona).</li>
<li>Seventeen additional starts are scheduled through the remainder of 2024.</li>
</ul>
&#8220;Altogether presenting few avenues to emerge from remaining a going concern,&#8221; the analyst says. JP Morgan has downgraded from <a href="https://www.benzinga.com/quote/BLUE/analyst-ratings" target="_blank" rel="noreferrer noopener">Neutral to Underweight</a>.
The analyst writes that the proxy vote did not gather enough support to approve a reverse stock split and increase the number of shares available for issuance. This outcome effectively eliminates equity financing as an option for raising capital.
In September, Bluebird bio implemented a restructuring to optimize its cost structure and enable quarterly cash flow break-even in the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41008825/gene-therapy-focused-bluebird-bio-restructures-cuts-is-workforce-by-25-seeks-to-breakeven-next-ye" rel="noreferrer noopener">second half of 2025</a>.
Price Action: BLUE stock is down 11.2% at $0.32 at last check Friday.
Photo by Ground Picture on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012924/mullen-drives-into-government-sector-with-electric-bollinger-b4-trucks" target="_blank" rel="noreferrer noopener">Mullen Drives Into Government Sector With Electric Bollinger B4 Trucks</a></li>
</ul>

Analyst Color

Earnings

Downgrades

Analyst Ratings

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

RBC Capital analyst Luca Issi reiterates bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Sector Perform and maintains $4 price target.

Price Target

Reiteration

RBC Capital Reiterates Sector Perform on bluebird bio, Maintains $4 Price Target

B of A Securities analyst Jason Gerberry downgrades bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) from Buy to Neutral and lowers the price target from $3 to $0.5.

B of A Securities Downgrades bluebird bio to Neutral, Lowers Price Target to $0.5

Barclays analyst Gena Wang maintains bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Overweight and lowers the price target from $4 to $2.

Barclays Maintains Overweight on bluebird bio, Lowers Price Target to $2

Guidance

bluebird bio Sees Q4 2024 Revenue At Least $25M Vs $27.85M Estimate

bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. The company reported quarterly sales of $10.60 million which missed the analyst consensus estimate of $18.05 million by 41.27 percent. This is a 14.46 percent decrease over sales of $12.39 million the same period last year.

Comments

bluebird bio

bluebird bio (BLUE) オプション

bluebird bio (NASDAQ:BLUE) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル